GeneReach Biotechnology (4171) - Total Liabilities

Latest as of December 2025: NT$284.34 Million TWD ≈ $8.96 Million USD

Based on the latest financial reports, GeneReach Biotechnology (4171) has total liabilities worth NT$284.34 Million TWD (≈ $8.96 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore GeneReach Biotechnology (4171) net asset momentum to track the company's year-over-year net asset growth rate.

GeneReach Biotechnology - Total Liabilities Trend (2017–2025)

This chart illustrates how GeneReach Biotechnology's total liabilities have evolved over time, based on quarterly financial data. See GeneReach Biotechnology free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

GeneReach Biotechnology Competitors by Total Liabilities

The table below lists competitors of GeneReach Biotechnology ranked by their total liabilities.

Company	Country	Total Liabilities
Unifin Financiera S. A. B. de C. V MX:UNIFINA	Mexico	MX$83.80 Billion
Battalion Oil Corp NYSE MKT:BATL	USA	$511.94 Million
Genoway PA:ALGEN	France	€20.43 Million
Gabriel Resources Ltd V:GBU	Canada	CA$23.73 Million
Malmbergs Elektriska AB (publ) ST:MEAB-B	Sweden	Skr157.75 Million
TINYBUILD REGSCAT3 DL-001 F:8Z3	Germany	€11.50 Million
Tycoons Worldwide Group (Thailand) Public Company Limited BK:TYCN	Thailand	฿1.94 Billion
Systech Bhd KLSE:0050	Malaysia	RM290.19 Million

Liability Composition Analysis (2017–2025)

This chart breaks down GeneReach Biotechnology's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 4171 stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.41	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.48	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.32	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how GeneReach Biotechnology's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for GeneReach Biotechnology (2017–2025)

The table below shows the annual total liabilities of GeneReach Biotechnology from 2017 to 2025.

Year	Total Liabilities	Change
2025-12-31	NT$284.34 Million ≈ $8.96 Million	-16.62%
2024-12-31	NT$341.00 Million ≈ $10.74 Million	+8.70%
2023-12-31	NT$313.71 Million ≈ $9.88 Million	-39.58%
2022-12-31	NT$519.23 Million ≈ $16.36 Million	-12.93%
2021-12-31	NT$596.35 Million ≈ $18.79 Million	+55.81%
2020-12-31	NT$382.75 Million ≈ $12.06 Million	+128.07%
2019-12-31	NT$167.82 Million ≈ $5.29 Million	-56.15%
2018-12-31	NT$382.68 Million ≈ $12.06 Million	+8.65%
2017-12-31	NT$352.21 Million ≈ $11.10 Million	--

About GeneReach Biotechnology

TWO:4171 Taiwan Biotechnology

Market Cap

$31.08 Million

NT$986.48 Million TWD

Market Cap Rank

#23579 Global

#1474 in Taiwan

Share Price

NT$17.35

Change (1 day)

+3.27%

52-Week Range

NT$16.70 - NT$26.50

All Time High

NT$246.40